Beam Therapeutics Valuation
| BEAM Stock | USD 25.05 1.47 6.23% |
At this time, the firm appears to be undervalued. Beam Therapeutics shows a prevailing Real Value of $34.63 per share. The current price of the firm is $25.05. Our model approximates the value of Beam Therapeutics from analyzing the firm fundamentals such as return on equity of -0.18, and Profit Margin of (0.41) % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Beam Therapeutics' valuation include:
Price Book 2.6213 | Enterprise Value 1.3 B | Enterprise Value Ebitda (7.03) | Price Sales 5.9326 | Enterprise Value Revenue 3.7484 |
Undervalued
Today
Please note that Beam Therapeutics' price fluctuation is not too volatile at this time. Calculation of the real value of Beam Therapeutics is based on 3 months time horizon. Increasing Beam Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Beam stock is determined by what a typical buyer is willing to pay for full or partial control of Beam Therapeutics. Since Beam Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Beam Stock. However, Beam Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 25.05 | Real 34.63 | Target 67.0 | Hype 25.06 | Naive 22.07 |
The intrinsic value of Beam Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Beam Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Beam Therapeutics helps investors to forecast how Beam stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Beam Therapeutics more accurately as focusing exclusively on Beam Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Beam Therapeutics' intrinsic value based on its ongoing forecasts of Beam Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Beam Therapeutics' closest peers.
Beam Therapeutics Cash |
|
Beam Valuation Trend
Knowing Beam Therapeutics' actual value is paramount for traders when making sound investment determinations. Using both Beam Therapeutics' enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Beam Therapeutics Total Value Analysis
Beam Therapeutics is currently forecasted to have valuation of 1.31 B with market capitalization of 2.07 B, debt of 173.17 M, and cash on hands of 1.09 B. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Beam Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.31 B | 2.07 B | 173.17 M | 1.09 B |
Beam Therapeutics Investor Information
About 93.0% of the company shares are held by institutions such as insurance companies. The book value of Beam Therapeutics was currently reported as 9.97. The company recorded a loss per share of 1.58. Beam Therapeutics last dividend was issued on the February 4, 2014. The entity had 2:1 split on the October 26, 1990. Based on the key indicators related to Beam Therapeutics' liquidity, profitability, solvency, and operating efficiency, Beam Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December.Beam Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Beam Therapeutics has an asset utilization ratio of 25.88 percent. This suggests that the Company is making $0.26 for each dollar of assets. An increasing asset utilization means that Beam Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Beam Therapeutics Ownership Allocation
Beam Therapeutics holds a total of 82.81 Million outstanding shares. The majority of Beam Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Beam Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Beam Therapeutics. Please pay attention to any change in the institutional holdings of Beam Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Beam Therapeutics Profitability Analysis
The company reported the previous year's revenue of 377.71 M. Net Loss for the year was (132.53 M) with loss before overhead, payroll, taxes, and interest of (250.67 M).About Beam Therapeutics Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Beam Therapeutics. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Beam Therapeutics based exclusively on its fundamental and basic technical indicators. By analyzing Beam Therapeutics's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Beam Therapeutics's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Beam Therapeutics. We calculate exposure to Beam Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Beam Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -59.7 M | -56.7 M | |
| Pretax Profit Margin | (0.35) | (0.36) | |
| Operating Profit Margin | (0.47) | (0.49) | |
| Net Loss | (0.35) | (0.37) | |
| Gross Profit Margin | (0.16) | (0.17) |
Beam Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Beam Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 77.2 M |
Beam Therapeutics Current Valuation Indicators
Beam Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Beam Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Beam Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Beam Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Beam Therapeutics' worth.When determining whether Beam Therapeutics is a strong investment it is important to analyze Beam Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Beam Therapeutics' future performance. For an informed investment choice regarding Beam Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Beam Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. To learn how to invest in Beam Stock, please use our How to Invest in Beam Therapeutics guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Beam Therapeutics. If investors know Beam will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Beam Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.58) | Revenue Per Share 4.273 | Quarterly Revenue Growth (0.17) | Return On Assets (0.09) | Return On Equity (0.18) |
The market value of Beam Therapeutics is measured differently than its book value, which is the value of Beam that is recorded on the company's balance sheet. Investors also form their own opinion of Beam Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Beam Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Beam Therapeutics' market value can be influenced by many factors that don't directly affect Beam Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Beam Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Beam Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Beam Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.